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Summary.-High-mol.-wt levan injected locally inhibits the growth of Lewis lung
carcinoma in C57BL mice. The inhibition is dependent on the number oftumour cells
injected and on the dose of levan. The inhibition decreases tumour incidence and size
as well as prolonging survival. The polysaccharide is most effective when injected
daily beginning on the day of tumour-cell inoculation. Treatment begun on later
dates is less effective. Treatment begun one day before tumour-cell inoculation
enhances tumour growth. Histological studies showed that levan induces an intense
polymorphonuclear (PMN) reaction followed by accumulation of vacuolated, levan-
laden macrophages. Both PMN and activated macrophages seemed to have an
inhibitory effect upon the growth of the tumour. The effector role of PMN was not
explained by the histological study. Tumour cells in close contact with levan-laden
macrophages appeared mostlynecrotic. Administration oflevanbegun one daybefore
tumour-cell inoculation produced a similar reaction, but the infiltrating cells did not
appear to approach and damage the tumour cells.
LEVAN, a high-mol.-wt polyfructoside,
has been shown to prevent the passage of
cells (Shilo et al., 1956) and macro-
molecules (Davies, et al., 1955; Behar &
Shilo, 1969) from blood vessels to tissues.
It is probably this property which leads to
its observed inhibitory effect on acute
inflammatory response (Shilo et al., 1956)
and wound healing (Wolman & Wolman,
1956).
Levan inhibits the passage of cells from
blood to tissues in processes in which this
passage is deleterious (e.g. graft rejection
(Leibovici et al., 1975) and experimental
allergic encephalomyelitis (Berman et al.,
1976)).
It has been shown (Wolman, 1956) that
the reaction of tissues to repeated injec-
tions of levan consists mainly of pro-
liferation of macrophages and their trans-
formation into swollen levan-filled foamy
cells. Levan was found to induce morpho-
logical (Robertson et al., 1977) and func-
tional (not yet published) changes in
macrophages.
It has been further shown that levan is
animmunologically active agent (Coutinho
& Moller, 1973; Hoenig et al., 1978;
Shezen etal., 1978). Wethereforeenvisaged
the possibility that levan could modify the
immune reaction of the host to cancer.
In fact we found that levan has an in-
hibitory effect on the development of
AKR lymphoma (Leibovici et al., 1975;
Sinai etal., 1976). Wepresenthere observa-
tions showing that levan administration
exerts an inhibitory effect on an epithelial
tumour, Lewis lung carcinoma.
Many other polysaccharides have been
shown to inhibit tumour growth, and the
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subject has been reviewed by Whistler
et al. (1976). The antitumoral effect of
various polysaccharides was explained by
different mechanisms. A direct cytotoxic
effect on tumour cells was suggested by
Belkin et al. (1959) for different poly-
saccharides of higher plants, and by Roe
(1972) for gum tragacanth. A host-
mediated effect was implicated for other
polysaccharides, as for instance methyl-
cellulose (Lazar & Lazar, 1962) and
lentinan (Maeda & Chihara, 1971). An
effect of bacterial polysaccharides on
blood supply to tumours was suggested by
Algire et al. (1952).
The present study shows that the cel-
lular reaction to tumour cells induced by
levan treatment might be the principal
factor underlying inhibition of tumour
growth.
MATERIALS AND METHODS
Mice.-C57BL/6J 6-week-old mice were
obtained from the Weizmann Institute of
Science, Rehovot, Israel and the Lewis lung
carcinoma was kindly supplied by Professor
N. Trainin ofthe Department of Cell Biology
at the same Institute. Each of the results
presented is representative of 3-5 experi-
ments, composed of 10 mice per group.
Tumour-cell inoculation.-Non-necrotic tu-
mour fragments were suspended in Dulbecco-
Vogt medium, minced, and filtered through
several layers of gauze to obtain a cell sus-
pension. Cells were counted in a haema-
cytometer using the trypan-blue-exclusion
test as a criterion of viability. All steps
were taken at 4°C. Freshly prepared tumour
cells (2x 105) were inoculated s.c. into the
backs ofthe animals.
Levan treatment.-Native Aerobacter levan
prepared according to Hestrin et al. (1954)
was purchased from the Department of
Biological Chemistry Technical Unit, The
Hebrew University of Jerusalem. Its mol. wt
was -20 x 106. A 5% solution of the above in
saline was prepared according to Shilo et al
(1956). Five or 10 mg of levan was injected
in the region of the tumour-cell inoculation,
beginning on Days -1, 0, 2, or 5 after inocu-
lation. Injections were continued daily until
the end of the experiments.
Evaluation of tumour growth.-Tumour
growth was determined every 3-5 days by
palpation and measurements of the diameter
inmm. Whenthetumourhaddifferentvertical
and horizontal diameters, their average was
taken. Recording of tumour size was stopped
when the first mouse in the group died.
Histological study.-Six groups of at least
15 mice each were used. In Group 1 the
animals were inoculated with tumour-cell
suspension and not otherwise treated. Group
2 mice were given daily s.c. levan injections
only. The levan was injected into the area of
the back that was used for tumour-cell
inoculation in the other animals. In Group 3
the animals were injected daily with levan
administered topically from the day before
the tumour inoculation. In Group 4 topical
levan treatment was begun simultaneously
with tumour-cell inoculation, while in Group
5 the topical levan injections were started on
the day after, and in Group 6, 2 days after
tumour inoculation.
Three animals of each group were killed:
4 h, 1 day, 2 days, 7 days and 14 days after
inoculation ofthe tumour cells, and in Group
2 after the start of levan injections. The area
of tumour-cell and levan inoculation was
excised with a wide margin, fixed in 10%
formalin and stained with haematoxylin and
eosin.
RESULTS
Tumour growth dependence on levan dose
Fig. 1 shows the effect of different
doses of levan on tumour size. A 10mg
daily dose was more efficient than a 5mg
dose. The inhibition of neoplastic growth,
as judged by the average size of tumours,
was 89% with 10 mg and 48% with 5 mg of
levan.
Influence of levan on survival of tumour-
inoculated mice
Fig. 2 shows that on Day 31 after
tumour-cell inoculation, when all of the
untreated mice were dead, 75% of the
levan-treated mice were still alive. On the
day of 50% survival of the untreated
mice, 90% were still alive in the treated
group. 50% ofthe treated mice were alive
and without tumours 230 days after
tumour inoculation, although treatment
was stopped at 116 days. The increase in
life expectancy due to levan treatment was
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DAYS AFTER TUMOUR CELL INOCULATION
FIG. 1.-Effect of levan dose on Lewis lung
carcinoma size as a function of time. Each
curve represents 10 mice. Tumour inocula-
tion: 2 x 105 cells s.c. in back. Levan dose
daily from Day 0 in 4;region of tumour
inoculation.










FIG. 3.Effect of varying the time of begin-
ning levan treatment on size of tumour.
Each group included 10 mice. Tumour-cell
inoculation as before.
L1, Untreated. I, Treatment begun on
Day 0. *, Treatment begun on Day 2.
Z, Treatment begun on Day 5.
In all these experiments no metastatic
spread of tumours was seen.
Effect of varying the time of beginning of
levan treatment on tumour incidence
Fig. 3 shows the dependence of tumour
development on the time when treatment
was started. Treatment begun on Day 0
was more effective than treatment started
OWS AFTER TUMOUR INOCUATION
FIG. 2. Effect of levan on survival of Lewis-
lung-carcinoma-inoculated mice. 2 x 105
tumourcells were inoculated into the backof
each mouse on Day 0. Levan was topically
injected at a daily dose of 10 mg beginning
from Day 0. Each group included 8 mice.
0, UJntreated. A, Levan-treated.
always present, but varied between experi-
ments.
As can be seen in Fig. 2, in this experi-
mentthe incidence oftumours inthelevan-
treated group was 50%. In other experi-
ments the incidence of tumours in mice
treated with daily doses of 10 mg levan
varied between 30 and 90%.
D AFTER TUMOUR NOCULATON
FIG. 4. Comparison ofthe effect oftreatment
begun before tumour inoculation on Day 0.
Each group included 10 mice. Tumour and
levan injection as before.
0, Untreated. *, Treatment begun on
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FiG. 5. Untreated mouse of Group 1 inoculated with tumour cells 14 days earlier. Tumour mass
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Fie. 6.-Levan treatment only, 4 h after levan
surrounded by a rim of p
later. On Day 10 after tumour-cell inocu-
lation, treatment begun on Day 0 caused
a 63% inhibition (as judged by tumour
size) whilst treatment begun on Day 2
produced 42% inhibition, and that begun
injection (Group 2). Amorphous mass on the left
oolymorphs. H. & E. x 200.
on Day 5 was almost ineffective (around
Day 5 tumours were just palpable). In
one experiment survival was slightly
improved even when treatment was begun
as late as Day 7.
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FIa. 7.-Levan treatment only (Group 2). Vacuolated macrophages with early proliferation of
fibroblasts and capillaries on Day 14. H. & E. x 200.
FiG. 8.-Mouse injected with levan beginning on the day before tumour-cell inoculation (Group 3)
24 h after tumour injection. On the right, polymorphs and amorphous material. On the left, large
apparently undamaged tumour cells. H. & E. x 400.
Fig. 4shows thattreatmentbegunbefore
tumour-cell inoculation enhanced tumour
development. Mortality in animals treated
from Day -1 was earlier than in un-
treated mice.
Histologicalfindings
Group 1: Tumour development in un-
treated animals.-Four hours after tumour
inoculation, the injected area contained
small groups of tumour cells, the majority
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of which were necrotic or disintegrating.
Few isolated PMNs appeared around and
between tumour cells. One and 2 days after
inoculation, most tumour cells were nec-
rotic, and only few large tumour cells were
seen between the necrotic debris, inter-
mingled with a few polymorphs. At 7 and
14 days the tumours were large solid
masses of pleomorphic cells with no in-
flammatory reaction around them (Fig. 5).
The tumour infiltrated adjacent muscle
and adipose tissue. Many mitotic figures
were found in the tumour cells.
Group 2: Levan treatment only.-Four
hours after s.c. injection of levan an
amorphous fibrillary eosinophilic material
surrounded by PMNs was seen in the lower
dermis (Fig. 6). Twenty-four hours after
the injection the mass of eosinophilic
material was still present surrounded and
infiltrated by a large number of poly-
morphs. In the centre of the mass there
was a very dense accumulation of poly-
morphs. Few macrophages with abundant
vacuolar cytoplasm were seen at the
margin of the eosinophilic material. At
Day 2 the number of polymorphs at the
periphery was diminished, and many
vacuolated macrophages were seen around
and within the amorphous eosinophilic
material. At 7 and 14 days, only a few
PMNs were present and the whole area
was studded with foamy macrophages. On
Day 14, in addition to the macrophages,
a few proliferating fibroblasts and capil-
laries were found (Fig. 7).
Group 3: Topically injected levan from
1 day before tumour-cell inoculation.-Four
hours after tumour-cell inoculation a few
isolated tumour cells were seen scattered
between PMNs and near the amorphous
material. After 1 day more isolated tumour
cells were seen. Numerous PMNs infiltra-
ted the area with no obvious signs of
attraction to tumour cells. In many places
the PMNs surrounded deeply stained
amorphous masses which might have been
dead tumour cells. Apparently undamaged
tumour cells were found inside and at the
periphery of the area of polymorph infil-
tration (Fig. 8). On Day 2 a mixture of
largetumour cells, PMNs and macrophages
was present. Also here the tumour cells
bore no apparent relation to the infiltrate,
and tumour cells adjacent to macrophages
appeared undamaged (Fig. 9). On Days 7
and 14 large solid tumour masses were seen
infiltrating into the neighbouring tissues,
surrounded by numerous PMNs and
macrophages. In the dense peripheral
infiltrate of polymorphs and macrophages
scattered tumour cells were visible. On
Day 14 a large solid tumour mass con-
sisting of undamaged cells was surrounded
by a rim ofvacuolated macrophages.
Group 4: Topical levan treatment begun
simultaneously with tumour inoculation.-
Four hours and 1 day after tumour-cell
inoculation, small groups of isolated
tumour cells, many ofthem necrotic, were
seen. A heavy infiltrate of PMNs was
found around and between the tumour
cells, and in the eosinophilic material.
Some of the tumour cells surrounded by
the infiltrate appeared shrunken and
homogeneously basophilic (Fig. 10). On
Day 1 many vacuolated macrophages were
already visible. On Day 2 the findings
were similar to those of Day 1. On Day
7 only in one animal was a small group of
tumour cells seen, surrounded by a
necrotic area with abundant PMNs and
vacuolated macrophages. In the 2 other
animals no tumour cells were detected.
On Day 14 small groups of tumour cells
surrounded by dense infiltrates of foamy
macrophages were found in 2 animals.
Macrophages were also seen penetrating
into the mass of tumour cells, giving them
a "starry sky" appearance (Fig. 11). The
tumour cells impinging on the macro-
phages were mostly shrunken and hyper-
chromatic, with no demarcation between
nucleus and cytoplasm, or with relatively
small hyperchromatic naked nuclei. The
tumour cells not in contact with macro-
phages were large, with a round nucleus,
2-3 large nucleoli, and abundant baso-
philic cytoplasm (Fig. 12).
Group 5: Topical levan injection starting
1 day after tumour inoculation.-On Day 1
isolated tumour cells were seen surrounded
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F.IG. 9.-Mouse treated in the same way in Fig. 8, but injected 2 days after tumour-cell inoculation.
A heavy infiltrate with polymorphs and macrophages. Between these cells a number of undamaged
tumour cells (arrows). H. & E. x 400.
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FIG. 10. A mouse of Group 4, started on levan simultaneously with the tumour-cell inoculation,
examined 1 day after inoculation. A few isolated tumour cells in the centre surrounded by massive
polymorph infiltration. Some tumour cells are shrunken and basophilic. H. & E. x 200.
by polymorphs. On Day 2 and 7 dispersed
tumour cells were surrounded by a heavy
infiltrate of PMNs and macrophages. On
Day 14 the tumour was large and solid,
sharply delineated from the surrounding
tissue by a wide band ofvacuolated macro-
phages with a few polymorphs. In a few
areas macrophages were seen inside the
solid tumour mass. The macrophage reac-
tion was less intense than in the mice of
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FIG. 11.-Mouse of Group 4, at Day 14. Large vacuolated macrophages between tumour cells, giving
the tumour a "starry sky" appearance. Tumour cells impinging on macrophages show degenerative
changes which are better seen in Fig. 12. H. & E. x 200.
FIG. 12.-Same mouse as in Fig. 11. Tumour cells impinging on the large vacuolated macrophages
(short arrow) are shrunken, homogeneous and hyperchromatic. Tumour cells not in contact with
macrophages appear healthy (long arrow). H. & E. x 1330.
Group 4, but the changes in tumour cells
impinging on macrophages were similar.
Group 6: Topical levan injection startiny
2 days after tumour inoculation.-On Day
2 few isolated tumour cells were embedded
in a mass of polymorphs. On Day 7 small
groups of isolated tumour cells were sur-
rounded by mononuclear cells and many
vacuolated macrophages. On Day 14 a
solid tumour mass with areas of necrosis
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was surrounded by a thick rim of vacuo-
lated macrophages, many of which were
seen penetrating the tumour mass. The
macrophage reaction was still less than in
Group 5 mice, but the changes in tumour
cells in contact with macrophages were
similar.
DISCUSSION
The experimental results indicate that
levan inhibited the growth of Lewis lung
carcinoma, in addition to its previously
reported effect on AKR lymphoma. This
inhibition was manifested by a decrease
in the rate of tumour growth, judged by
the incidence and size of the tumours, as
well as by prolonged survival of the mice.
The antitumour activity of levan could
be due to one or more of the following
mechanisms: (1) levan might be directly
cytotoxic to the tumour cells; (2) it might
induce a direct but not cytotoxic change in
tumour cells, rendering them eventually
more sensitive to other tumoricidal in-
fluences; (3) the polysaccharide might
enhance the host's reaction against the
tumour cells.
The enhancement of tumour growth in
animals treated from Day -1 indicates
that mechanisms other than direct cyto-
toxicity are operating in the antitumour
effect of levan. In fact, administration of
levan before tumour-cell inoculation in-
creases the local concentration ofthe drug
and could be expected to be more efficient
than treatment begun on the day of
inoculation, if a direct effect were impli-
cated. Other studies in ourlaboratory have
shown that levan is not directly cytotoxic
to tumour cells in vitro (Brudner et al.,
in preparation), although it induces a
change in permeability of these cells.
S.c. injection of levan was shown to
elicit an acute inflammatory reaction
followed by growth of macrophage-rich
granulation tissue. This is consistent with
the findings of Spector et al. (1968), who
observed a similar reaction with dextrans.
Thus levan, which inhibits cellular in-
filtration when systemically administered,
provokes such reaction by topical adminis-
tration.
The present study shows that the
development of Lewis lung carcinoma
inoculated s.c. in mice was inhibited by to-
pically injected levan, mainly through the
host's reaction. Whereas the inoculation
of tumour alone did not cause any host
reaction, the levan-treated animals reacted
in the first 24 h with an intense poly-
morphonuclear (PMN) infiltration, fol-
lowed by accumulation of vacuolated
macrophages. Already during the first 2
days after tumour inoculation and simul-
taneous levan treatment, the tumours
were smaller than in the non-levanized
animals, with extensive necrosis oftumour
cells in the vicinity ofthe PMN and macro-
phage infiltration. This finding indicates a
possibly important role of PMNs and
macrophages in the defence mechanism
against tumours.
Intensive PMN reaction was found by
Hanna et al. (1972) in tumour regression
after injection of BCG into the tumour.
Similar findings were reported by Lieber-
man et al. (1975) after BCG injection into
human malignant melanoma. Snodgrass
etal. (1975) also described PMNinfiltration
into transplanted lung carcinoma treated
with pyran copolymer. The precise role
of PMNs in tumour-cell destruction is
unknown. Clark&Klebanoff(1975)demon-
strated a cytotoxic effect of human PMNs
on neoplastic cells. These authors postula-
ted killing of tumour cells by the peroxi-
dase system. Clark et al. (1975) and
Strauss et al. (1974) showed an inhibitory
effect of blood-cell peroxidase systems on
tumour cells.
Numerous authors claim that histio-
cytes are the major effector cells in tumour
regression. The mechanism by which
macrophages destroy tumour cells is not
quite clear. Hanna et al. (1972) and
Lieberman et al. (1975) suggest that BCG
activates both specific and nonspecific
immune responses, which increase age
killing oftumour cells by activated macro-
phages. Feldman et al. (1974) showed
phagocytosis of tumour cells by macro-
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phages. Chambers & Weiser (1969) also
showed that activatedmacrophagesphago-
cytose portions of tumour cells.
Another mechanism for the cytotoxicity
of activated macrophages against tumour
cells was suggested by Hibbs (1974) who
demonstrated transfer oflysosomes to the
tumour cells from activated macrophages.
Snodgrass & Hanna (1973) showed that
tumour cells were killed when they were in
close contact with the plasma membrane
of BCG-activated macrophages. A similar
finding was reported by Snodgrass et al.
(1975) who demonstrated that intimate
contact between pyran-activated histio-
cytes and carcinoma cells was associated
with degeneration of the tumour cells.
Cells of Lewis lung carcinoma were
shown by Fauve et al. (1974) to be able to
repulse macrophages in vitro. Levan seems
to overcome this property of the Lewis
lung carcinoma cells, since macrophages
were seen to approach tumour cells. Histo-
logical examination showed vacuolated
levan-laden macrophages encircling and
penetrating the tumour masses. Tumour
cells in close contact with the activated
macrophages showed shrunken nuclei and
cell bodies, and various stages of necrosis.
Tumour cells not in close contact with
macrophages appeared unchanged. No
phagocytosis of tumour cells by macro-
phages was seen. Lately, Bomford &
Moreno (1977) showed an in vitro anti-
tumour effect of cytostatic macrophages
induced by levan. They actually showed
that macrophages activated by low doses
of levan had an antitumour effect, but
practically only in vitro. A stimulated
macrophage reaction around the tumour
was found for other polysaccharides by
Tokuzen (1973). Another, non-polysac-
charide polymer, pyran, has been shown
by Schultz et al. (1977) to have a similar
effect.
Our findings are in agreement with the
studies of Snodgrass & Hanna (1973) and
Snodgrass et al. (1975) showing intimate
contact between activated macrophages
and tumour cells. This conclusion is sup-
ported by yet unpublished results which
show that macrophages harvested from
theperitoneum oflevan-treated mice delay
tumour appearance. Levan seems to
represent an efficient activator of macro-
phages.
The administration of levan beginning
on the day before tumour-cell inoculation
was shown to enhance tumour growth. A
similar effect of preliminary treatment
with levan was found in the AKR lym-
phoma (Sinai et al., 1976). The microscopic
findings described here might contribute
to the understanding of this phenomena;
although levan injection produced a PMN
and macrophage response, the cells ap-
peared not to have been attracted to the
tumour cells and not to damage them.
In addition, levan administered before
the injection oftumour cells may block the
RES. Impairment ofmacrophage function
was shown by others to enhance tumour
growth (Isa & Sanders, 1975).
This study was in part supported by a grant from
the Israel Cancer Society.
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